Hotchkis & Wiley Capital Management LLC bought a new stake in Solventum Co. (NYSE:SOLV - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 1,799,880 shares of the company's stock, valued at approximately $125,488,000. Hotchkis & Wiley Capital Management LLC owned approximately 1.04% of Solventum as of its most recent SEC filing.
A number of other institutional investors also recently made changes to their positions in the business. Copeland Capital Management LLC bought a new position in Solventum during the 3rd quarter worth $26,000. Mather Group LLC. purchased a new stake in Solventum in the 3rd quarter worth about $27,000. EverSource Wealth Advisors LLC purchased a new stake in Solventum in the 1st quarter worth about $30,000. Hollencrest Capital Management purchased a new stake in Solventum in the 2nd quarter worth about $25,000. Finally, True Wealth Design LLC increased its position in Solventum by 23,550.0% in the 3rd quarter. True Wealth Design LLC now owns 473 shares of the company's stock worth $33,000 after purchasing an additional 471 shares during the last quarter.
Solventum Stock Performance
NYSE SOLV traded down $1.24 during trading on Tuesday, reaching $70.75. 1,254,569 shares of the company's stock were exchanged, compared to its average volume of 1,682,539. The business has a 50 day moving average price of $70.55 and a 200-day moving average price of $62.58. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. Solventum Co. has a fifty-two week low of $47.16 and a fifty-two week high of $96.05.
Analyst Ratings Changes
SOLV has been the topic of several research reports. Morgan Stanley upped their target price on Solventum from $60.00 to $73.00 and gave the stock an "equal weight" rating in a research report on Monday, November 11th. Piper Sandler raised their price objective on Solventum from $71.00 to $75.00 and gave the stock a "neutral" rating in a research report on Friday, November 8th. Wells Fargo & Company reduced their price objective on Solventum from $69.00 to $64.00 and set an "equal weight" rating for the company in a research report on Friday, August 9th. The Goldman Sachs Group raised their price objective on Solventum from $48.00 to $54.00 and gave the stock a "sell" rating in a research report on Monday, August 12th. Finally, Stifel Nicolaus began coverage on Solventum in a research report on Tuesday, October 8th. They issued a "buy" rating and a $82.00 price objective for the company. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, Solventum presently has a consensus rating of "Hold" and an average price target of $68.00.
Check Out Our Latest Stock Report on Solventum
Solventum Profile
(
Free Report)
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.
Further Reading
Before you consider Solventum, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solventum wasn't on the list.
While Solventum currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
